Datapoint: FDA Delays New Leqembi Launch

The launch of a new version of Eisai and Biogen’s Leqembi (lecanemab) has been delayed, with the FDA requesting additional information about the Alzheimer’s drug. The FDA wants more data about the effectiveness of subcutaneous injection relative to infusion, Leqembi’s current form of administration. Currently, Leqembi must be infused onsite in a clinical setting every two weeks. The drugmakers hope that a switch to biweekly injections will reduce the burden of administration for practitioners and speed adoption of the drug, which Eisai admits has been slower than hoped. For the treatment of Alzheimer’s disease, 38% of all insured lives have covered or better access to Leqembi under the medical benefit.

SOURCE: MMIT Analytics, as of 4/16/24

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 16

Datapoint: Cigna, Oscar to End Small Group Partnership

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 15

Datapoint: FDA Approves Pfizer’s Hemophilia B Treatment

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 14

Datapoint: Sandoz Reaches Agreement With Amgen to Launch Prolia, Xgeva Biosimilars

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today